in the absence of a submission from the holder of the marketing authorisation
dupilumab (Dupixent®) is not recommended for use within NHSScotland.
Indication under review: As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice612KB (PDF)
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2324
- Indication:
As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
- Pharmaceutical company
- Sanofi Genzyme
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 18 January 2021